EU risks public health in its protection of big pharma monopolies
To secure a rapid and sufficient supply of vaccines and medicines, the global south has asked for a waiver of intellectual property rights. But despite the gravity of the situation, that is rejected outright by the EU. That should not come as a surprise. A briefing from CEO outlines the EU's traditional role as a staunch defender of big pharma monopolies, and how the push for provisions on 'data exclusivity' in trade agreements with third countries have seeked to undermine even existing flexibility under international rules.